VETERINARY ONCOLOGY MARKET ANALYSIS

Veterinary Oncology Market, By Animal Type (Companion Animal (Equine, Canine, and Feline) and Livestock Animal), By Therapy Type (Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy), By Mode of Administration (Oral and Intravenous), By Application (Canine Lymphoma, Osteosarcoma (OSA), Mast Cell Cancer, Melanoma, and Others), By Distribution Channel (Hospital Pharmacies, Government Agencies, and Retail Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : May 2024
Code : CMI2995
Pages :225
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Veterinary Oncology Market Regional Insights

To learn more about this report, Request sample copy

North America remains the dominant region in the global veterinary oncology market and is estimated to hold 36.9% of the market share in 2024 due to strong economic conditions and higher disposable incomes in countries like the U.S. and Canada that allow pet owners to spend more on advanced cancer treatments for their pets. Additionally, North America is home to many leading global players in veterinary oncology manufacturing which ensures easy access to high-quality cancer drugs, diagnostics and radiation therapy equipment across the region. Further, the rising adoption of pet insurance that now covers cancer treatments for insured pets has also propelled the market growth in North America.

The Asia Pacific region is poised to be the fastest growing market for veterinary oncology globally over the coming years. Countries like India, China, Japan and Australia are witnessing significant rise in pet adoption and increase in veterinary healthcare spending. According to recent surveys, affordability and accessibility of advanced cancer treatments for companion animals are improving consistently across both developing and developed nations in Asia Pacific. Local manufacturers are collaborating with global innovators to introduce affordable generic drugs and diagnostic tests in this region. Additionally, factors such as growing pet humanization, increasing pet ownership in urban areas and rising adoption of pain-free treatment options are supporting strong market penetration of novel oncology therapies in Asia Pacific.